Tag Archive for: Phase 3

Oncoinvent appoints Dr. Zuzana Jiráková Trnková as Chief Medical Officer to lead Phase 3 preparations for Radspherin®

  Dr. Jiráková Trnková brings more than 20 years of clinical development experience from Bayer, BioNTech, and Highlight Therapeutics, with expertise spanning global pivotal Phase III trials and alpha-emitting radiopharmaceuticals   Oslo, Norway – 28 October 2026 – Oncoinvent ASA (OSE: ONCIN), a clinical-stage radiopharmaceutical company developing Radspherin®, a receptor-independent alpha-emitting therapy to eradicate cancer […]

Hansa Biopharma announces ConfIdeS Phase 3 Abstract Selected for ‘What’s Hot, What’s New’ Plenary at ATC 2026

Lund, Sweden, June 24, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that the ConfIdeS Phase 3 abstract titled “Superior 1-year eGFR Among Highly Sensitized Patients Desensitized with Imlifidase Compared to Control” has been selected to be highlighted at the closing plenary session “What’s Hot, What’s New” at the American Transplant Congress (ATC) 2026, […]

Calliditas Announces Positive NefIgArd Open Label Extension Results

Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced that the global open-label extension (OLE) study to the Phase 3 NefIgArd study showed a treatment response consistent with the NefIgArd study across endpoints of urine protein to creatinine ration (UPCR) and estimated glomerular filtration rate (eGFR) at 9 months across all IgAN patients, including […]

Destiny Pharma plc – Positive findings from recent SAB meeting

Confirms proposed Phase 3 development pathway and identifies new life cycle management targets for XF-73 Nasal Brighton, United Kingdom – 6 July 2023 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development and commercialisation of novel medicines to prevent life threatening infections, recently held a meeting with its Scientific Advisory Board […]

Calliditas Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Full Approval of TARPEYO®

Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced the submission of a supplemental New Drug Application (“sNDA”) to the U.S. Food and Drug Administration (“FDA”) seeking full approval of TARPEYO® (budesonide) delayed release capsules for the entire study population from the Phase 3 NeflgArd study. TARPEYO is currently approved under accelerated approval to reduce […]

© Optimum Strategic Communications.